Dr. Reddy's Laboratories share news, announcements and annual reports
NSE: DRREDDYBSE: 500124Pharmaceuticals & BiotechnologyMid Cap
Dr. Reddy's Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1986 on BSE, May 2003 on NSE
Last close ₹1,352.00up ₹7.00 (0.52%)BSE ₹1,350.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,345.00.
30 Oct: open ₹1,345.00, high ₹1,363.70, low ₹1,345.00
52-week range of traded prices to 30 Oct 2026
₹1,101.00Low, 23 Jul 2026₹1,414.90High, 29 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,12,849 Cr104th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 40.30
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.91
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.59%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 6.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.15
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 17,14,05957.9% delivered
Dr. Reddy's Laboratories share news and announcements
1,702 announcements, routine notices left out, newest first. Page 22 of 35.
Jul 2017
Jun 2017
14 Jun · Legal
Exchange has sought clarification from the Company with respect to news item captioned "Dr Reddy's recalls 3.25L cartons Cipla-made acne drug from US". In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
May 2017
Apr 2017
3 Apr · News Verification
Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to recent news item captioned USFDA started Srikakulam inspection on march 27. No major observation from USFDA yet on Srikakulam plant. . In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.
Mar 2017
21 Mar · News Verification
Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to recent news item captioned "US FDA finds repeat observations from 2015 warning letter. Failed to maintain complete data to ensure compliance." In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.6 Mar · Legal
Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to announcement dated March 03, 2017, regarding a press release dated March 03, 2017, titled "Dr. Reddy's Laboratories announces acquisition of 100% stake in Imperial Credit Private Limited, a Non-Banking Finance Company (NBFC). On basis of above the Company is required to clarify following: 1. Name of the target entity, details in brief such as size, turnover etc;2. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";3. Brief details of any governmental or regulatory approvals required for the acquisition;4. Indicative time period for completion of the acquisition;5. Nature of consideration - whether cash consideration or share swap and details of the same;6. Percentage of shareholding / control acquired and / or number of shares acquired;7. Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).The response of the Company is awaited.
Feb 2017
16 Feb · Legal
Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to announcement dated 16-Feb-2017, regarding a press release dated February 16, 2017, titled "Dr. Reddy's announces US district court's opinion relating to patent infringement."On basis of above the Company is required to clarify following: 1. Expected financial implications, if any, due to compensation, penalty etc;2. Quantum of claims, if anyThe response of the Company is awaited.
Jan 2017